Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study

Jonas Wuopio; Jørgen Hilden; Carl Bring; Jens Kastrup; Ahmad Sajadieh; Gorm Boje Jensen; Erik Kjøller; Hans Jørn Kolmos; Anders Larsson; Janus Christian Jakobsen; Per Winkel; Christian Gluud; Axel C Carlsson; Johan Ärnlöv

doi:10.1016/j.atherosclerosis.2018.09.006

Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study

Jonas Wuopio, Jørgen Hilden, Carl Bring, Jens Kastrup, Ahmad Sajadieh, Gorm Boje Jensen, Erik Kjøller, Hans Jørn Kolmos, Anders Larsson, Janus Christian Jakobsen, Per Winkel, Christian Gluud, Axel C Carlsson, Johan Ärnlöv

11 Citationer (Scopus)

Abstract

BACKGROUND AND AIMS: The lysosomal cysteine proteases cathepsin B and S have been implicated in the atherosclerotic process. The present paper investigates the association between serum levels of cathepsin B and S and cardiovascular events and mortality in patients with stable coronary heart disease.

METHODS: The CLARICOR trial is a randomised, placebo-controlled trial investigating the effect of clarithromycin versus placebo in patients with stable coronary heart disease. The outcome was time to either a cardiovascular event or all-cause mortality. The placebo group was used as discovery sample and the clarithromycin group as replication sample: n = 1998, n = 1979; mean age (years) 65, 65; 31%, 30% women; follow-up for 10 years; number of composite outcomes n = 1204, n = 1220; respectively. We used a pre-defined multivariable Cox regression model adjusting for inflammation, established cardiovascular risk factors, kidney function, and use of cardiovascular drugs.

RESULTS: Cathepsin B was associated with an increased risk of the composite outcome in both samples after multivariable adjustment (discovery: multivariable ratio (HR) per standard deviation increase 1.12, 95% confidence interval (CI) 1.05-1.19, p < 0.001, replication; HR 1.14, 95% CI 1.07-1.21, p < 0.001). There was no significant association between cathepsin S and the composite outcome in either the discovery or replication sample after multivariable adjustment (p>0.45). Secondary analyses suggest that cathepsin B was predominantly associated with mortality rather than specific cardiovascular events.

CONCLUSIONS: Cathepsin B, but not serum cathepsin S, was associated with an increased risk of cardiovascular events in patients with stable coronary heart disease. The clinical implications of our findings remain to be established.

Originalsprog	Engelsk
Tidsskrift	Atherosclerosis
Vol/bind	278
Sider (fra-til)	97-102
Antal sider	6
ISSN	1567-5688
DOI	https://doi.org/10.1016/j.atherosclerosis.2018.09.006
Status	Udgivet - nov. 2018

Adgang til dokumentet

10.1016/j.atherosclerosis.2018.09.006

Citationsformater

Wuopio, J., Hilden, J., Bring, C., Kastrup, J., Sajadieh, A., Jensen, G. B., Kjøller, E., Kolmos, H. J., Larsson, A., Jakobsen, J. C., Winkel, P., Gluud, C., Carlsson, A. C., & Ärnlöv, J. (2018). Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. Atherosclerosis, 278, 97-102. https://doi.org/10.1016/j.atherosclerosis.2018.09.006

Wuopio, J, Hilden, J, Bring, C, Kastrup, J, Sajadieh, A, Jensen, GB, Kjøller, E, Kolmos, HJ, Larsson, A, Jakobsen, JC, Winkel, P, Gluud, C, Carlsson, AC & Ärnlöv, J 2018, 'Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study', Atherosclerosis, bind 278, s. 97-102. https://doi.org/10.1016/j.atherosclerosis.2018.09.006

@article{90e35ba29b064073959325fdf0bc6b57,

title = "Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study",

abstract = "BACKGROUND AND AIMS: The lysosomal cysteine proteases cathepsin B and S have been implicated in the atherosclerotic process. The present paper investigates the association between serum levels of cathepsin B and S and cardiovascular events and mortality in patients with stable coronary heart disease.METHODS: The CLARICOR trial is a randomised, placebo-controlled trial investigating the effect of clarithromycin versus placebo in patients with stable coronary heart disease. The outcome was time to either a cardiovascular event or all-cause mortality. The placebo group was used as discovery sample and the clarithromycin group as replication sample: n = 1998, n = 1979; mean age (years) 65, 65; 31%, 30% women; follow-up for 10 years; number of composite outcomes n = 1204, n = 1220; respectively. We used a pre-defined multivariable Cox regression model adjusting for inflammation, established cardiovascular risk factors, kidney function, and use of cardiovascular drugs.RESULTS: Cathepsin B was associated with an increased risk of the composite outcome in both samples after multivariable adjustment (discovery: multivariable ratio (HR) per standard deviation increase 1.12, 95% confidence interval (CI) 1.05-1.19, p < 0.001, replication; HR 1.14, 95% CI 1.07-1.21, p < 0.001). There was no significant association between cathepsin S and the composite outcome in either the discovery or replication sample after multivariable adjustment (p>0.45). Secondary analyses suggest that cathepsin B was predominantly associated with mortality rather than specific cardiovascular events.CONCLUSIONS: Cathepsin B, but not serum cathepsin S, was associated with an increased risk of cardiovascular events in patients with stable coronary heart disease. The clinical implications of our findings remain to be established.",

author = "Jonas Wuopio and J{\o}rgen Hilden and Carl Bring and Jens Kastrup and Ahmad Sajadieh and Jensen, {Gorm Boje} and Erik Kj{\o}ller and Kolmos, {Hans J{\o}rn} and Anders Larsson and Jakobsen, {Janus Christian} and Per Winkel and Christian Gluud and Carlsson, {Axel C} and Johan {\"A}rnl{\"o}v",

year = "2018",

month = nov,

doi = "10.1016/j.atherosclerosis.2018.09.006",

language = "English",

volume = "278",

pages = "97--102",

journal = "Journal of atherosclerosis research",

issn = "1567-5688",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years

T2 - a CLARICOR trial sub-study

AU - Wuopio, Jonas

AU - Hilden, Jørgen

AU - Bring, Carl

AU - Kastrup, Jens

AU - Sajadieh, Ahmad

AU - Jensen, Gorm Boje

AU - Kjøller, Erik

AU - Kolmos, Hans Jørn

AU - Larsson, Anders

AU - Jakobsen, Janus Christian

AU - Winkel, Per

AU - Gluud, Christian

AU - Carlsson, Axel C

AU - Ärnlöv, Johan

PY - 2018/11

Y1 - 2018/11

N2 - BACKGROUND AND AIMS: The lysosomal cysteine proteases cathepsin B and S have been implicated in the atherosclerotic process. The present paper investigates the association between serum levels of cathepsin B and S and cardiovascular events and mortality in patients with stable coronary heart disease.METHODS: The CLARICOR trial is a randomised, placebo-controlled trial investigating the effect of clarithromycin versus placebo in patients with stable coronary heart disease. The outcome was time to either a cardiovascular event or all-cause mortality. The placebo group was used as discovery sample and the clarithromycin group as replication sample: n = 1998, n = 1979; mean age (years) 65, 65; 31%, 30% women; follow-up for 10 years; number of composite outcomes n = 1204, n = 1220; respectively. We used a pre-defined multivariable Cox regression model adjusting for inflammation, established cardiovascular risk factors, kidney function, and use of cardiovascular drugs.RESULTS: Cathepsin B was associated with an increased risk of the composite outcome in both samples after multivariable adjustment (discovery: multivariable ratio (HR) per standard deviation increase 1.12, 95% confidence interval (CI) 1.05-1.19, p < 0.001, replication; HR 1.14, 95% CI 1.07-1.21, p < 0.001). There was no significant association between cathepsin S and the composite outcome in either the discovery or replication sample after multivariable adjustment (p>0.45). Secondary analyses suggest that cathepsin B was predominantly associated with mortality rather than specific cardiovascular events.CONCLUSIONS: Cathepsin B, but not serum cathepsin S, was associated with an increased risk of cardiovascular events in patients with stable coronary heart disease. The clinical implications of our findings remain to be established.

AB - BACKGROUND AND AIMS: The lysosomal cysteine proteases cathepsin B and S have been implicated in the atherosclerotic process. The present paper investigates the association between serum levels of cathepsin B and S and cardiovascular events and mortality in patients with stable coronary heart disease.METHODS: The CLARICOR trial is a randomised, placebo-controlled trial investigating the effect of clarithromycin versus placebo in patients with stable coronary heart disease. The outcome was time to either a cardiovascular event or all-cause mortality. The placebo group was used as discovery sample and the clarithromycin group as replication sample: n = 1998, n = 1979; mean age (years) 65, 65; 31%, 30% women; follow-up for 10 years; number of composite outcomes n = 1204, n = 1220; respectively. We used a pre-defined multivariable Cox regression model adjusting for inflammation, established cardiovascular risk factors, kidney function, and use of cardiovascular drugs.RESULTS: Cathepsin B was associated with an increased risk of the composite outcome in both samples after multivariable adjustment (discovery: multivariable ratio (HR) per standard deviation increase 1.12, 95% confidence interval (CI) 1.05-1.19, p < 0.001, replication; HR 1.14, 95% CI 1.07-1.21, p < 0.001). There was no significant association between cathepsin S and the composite outcome in either the discovery or replication sample after multivariable adjustment (p>0.45). Secondary analyses suggest that cathepsin B was predominantly associated with mortality rather than specific cardiovascular events.CONCLUSIONS: Cathepsin B, but not serum cathepsin S, was associated with an increased risk of cardiovascular events in patients with stable coronary heart disease. The clinical implications of our findings remain to be established.

U2 - 10.1016/j.atherosclerosis.2018.09.006

DO - 10.1016/j.atherosclerosis.2018.09.006

M3 - Journal article

C2 - 30261474

SN - 1567-5688

VL - 278

SP - 97

EP - 102

JO - Journal of atherosclerosis research

JF - Journal of atherosclerosis research

ER -

Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater